Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (NASDAQ: KURA) has announced the granting of inducement awards to four new employees as approved by the Company's Compensation Committee on April 1, 2025. The awards consist of nonstatutory stock options to purchase 79,500 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options have an exercise price of $6.38 per share, matching Kura's closing sales price on April 1, 2025. The vesting schedule spans four years, with 25% of shares vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.
Kura Oncology (NASDAQ: KURA) ha annunciato l'assegnazione di premi di indennità a quattro nuovi dipendenti, come approvato dal Comitato per la Compensazione dell'Azienda il 1° aprile 2025. I premi consistono in opzioni su azioni non statutarie per l'acquisto di 79.500 azioni di azioni ordinarie secondo il Piano di Opzioni di Indennità 2023 dell'Azienda.
Le opzioni su azioni hanno un prezzo di esercizio di $6,38 per azione, corrispondente al prezzo di chiusura delle vendite di Kura del 1° aprile 2025. Il piano di maturazione si estende su quattro anni, con 25% delle azioni che maturano dopo un anno e il saldo restante che matura mensilmente nei successivi 36 mesi, a condizione di un impiego continuativo.
Kura Oncology (NASDAQ: KURA) ha anunciado la concesión de premios de inducción a cuatro nuevos empleados, según lo aprobado por el Comité de Compensación de la Compañía el 1 de abril de 2025. Los premios consisten en opciones de acciones no estatutarias para comprar 79,500 acciones de acciones ordinarias bajo el Plan de Opciones de Inducción 2023 de la Compañía.
Las opciones de acciones tienen un precio de ejercicio de $6.38 por acción, que coincide con el precio de cierre de Kura el 1 de abril de 2025. El calendario de adquisición se extiende por cuatro años, con 25% de las acciones adquiriendo derecho después de un año y el saldo restante adquiriendo derecho mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo.
Kura Oncology (NASDAQ: KURA)는 2025년 4월 1일 회사 보상 위원회에서 승인된 바와 같이 네 명의 신규 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2023 유인 옵션 계획에 따라 79,500주의 보통주를 구매할 수 있는 비법적 주식 옵션으로 구성됩니다.
주식 옵션의 행사 가격은 $6.38 per share로, 2025년 4월 1일 Kura의 종가와 일치합니다. 권리 행사 일정은 4년에 걸쳐 있으며, 25%의 주식이 1년 후에 권리가 발생하고 나머지 잔액은 이후 36개월 동안 매달 권리가 발생합니다. 이는 계속 고용되는 것을 조건으로 합니다.
Kura Oncology (NASDAQ: KURA) a annoncé l'octroi de primes d'incitation à quatre nouveaux employés, comme approuvé par le Comité de Rémunération de l'Entreprise le 1er avril 2025. Les primes consistent en des options d'achat d'actions non statutaires pour acquérir 79 500 actions de l'action ordinaire dans le cadre du Plan d'Options d'Incitation 2023 de l'Entreprise.
Les options d'achat d'actions ont un prix d'exercice de $6,38 par action, correspondant au prix de clôture des ventes de Kura le 1er avril 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25% des actions acquérant des droits après un an et le reste acquérant des droits mensuellement pendant les 36 mois suivants, sous réserve de la continuité de l'emploi.
Kura Oncology (NASDAQ: KURA) hat die Gewährung von Anreizprämien an vier neue Mitarbeiter angekündigt, die am 1. April 2025 vom Vergütungsausschuss des Unternehmens genehmigt wurden. Die Prämien bestehen aus nicht-statutären Aktienoptionen zum Kauf von 79.500 Aktien des Stammkapitals gemäß dem Anreizoptionsplan 2023 des Unternehmens.
Die Aktienoptionen haben einen Ausübungspreis von $6,38 pro Aktie, was dem Schlussverkaufspreis von Kura am 1. April 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% der Aktien nach einem Jahr und der verbleibende Rest monatlich über die folgenden 36 Monate vesten, abhängig von der fortgesetzten Beschäftigung.
- Company demonstrates ability to attract new talent with equity compensation
- Potential shareholder dilution from 79,500 new stock options
SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,500 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
What is the exercise price for KURA's new stock options granted on April 1, 2025?
How many shares are included in KURA's April 2025 inducement stock option grants?
What is the vesting schedule for KURA's April 2025 inducement stock options?
How many employees received KURA's April 2025 inducement stock option grants?
